UNLABELLED: Small-molecule ligands specific for prostate-specific membrane antigen (PSMA) have the potential to improve prostate cancer imaging. However, highly charged ligands are difficult to label with 99mTc and to purify. In this study, we present an adamantane-trimerized small molecule that has nanomolar binding to PSMA and also has 12 negative charges. METHODS: To convert this molecule into a clinically viable SPECT diagnostic, we have developed a simple, cartridge-based, solid-phase prelabeling strategy that, within 25 min, converts readily available and inexpensive 99mTc-pertechnetate into a chemically pure complex, with a reactive N-hydroxysuccinimide (NHS) ester, in neat organic solvent. This stable intermediate can label any amine-containing small molecule or peptide with 99mTc in 1 step, with high specific activity and without the need for high-performance liquid chromatography (HPLC). RESULTS: Solid-phase conversion of 99mTc-pertechnetate to 99mTc-MAS3-NHS (MAS3 is S-acetylmercaptoacetyltriserine) could be completed in 25 min, with >99% radiochemical purity and with no coligands present. This intermediate was then conjugated to adamantane-trimerized GPI (2[(3-amino-3-carboxypropyl)(hydroxy)(phosphinyl)-methyl]pentane-1,5-dioic acid) in 1 step with >95% yield and no need for HPLC purification. The final molecule bound specifically to living human tumor cells expressing PSMA on their surface. Quantitative comparison was made among GPI monomer, GPI trimer, and their 99mTc-derivatives. CONCLUSION: Our study describes a simple cartridge-based conversion of 99mTc-pertechnetate to a useful, preloaded NHS ester intermediate that takes only 25 min to prepare and results in >99% radiochemical purity. Using this chemistry, we produced a high-specific-activity, 99mTc-labeled, PSMA-targeted small molecule and demonstrate gamma-ray radioscintigraphic imaging of living human prostate cancer cells.
UNLABELLED: Small-molecule ligands specific for prostate-specific membrane antigen (PSMA) have the potential to improve prostate cancer imaging. However, highly charged ligands are difficult to label with 99mTc and to purify. In this study, we present an adamantane-trimerized small molecule that has nanomolar binding to PSMA and also has 12 negative charges. METHODS: To convert this molecule into a clinically viable SPECT diagnostic, we have developed a simple, cartridge-based, solid-phase prelabeling strategy that, within 25 min, converts readily available and inexpensive 99mTc-pertechnetate into a chemically pure complex, with a reactive N-hydroxysuccinimide (NHS) ester, in neat organic solvent. This stable intermediate can label any amine-containing small molecule or peptide with 99mTc in 1 step, with high specific activity and without the need for high-performance liquid chromatography (HPLC). RESULTS: Solid-phase conversion of 99mTc-pertechnetate to 99mTc-MAS3-NHS (MAS3 is S-acetylmercaptoacetyltriserine) could be completed in 25 min, with >99% radiochemical purity and with no coligands present. This intermediate was then conjugated to adamantane-trimerized GPI (2[(3-amino-3-carboxypropyl)(hydroxy)(phosphinyl)-methyl]pentane-1,5-dioic acid) in 1 step with >95% yield and no need for HPLC purification. The final molecule bound specifically to living humantumor cells expressing PSMA on their surface. Quantitative comparison was made among GPI monomer, GPI trimer, and their 99mTc-derivatives. CONCLUSION: Our study describes a simple cartridge-based conversion of 99mTc-pertechnetate to a useful, preloaded NHS ester intermediate that takes only 25 min to prepare and results in >99% radiochemical purity. Using this chemistry, we produced a high-specific-activity, 99mTc-labeled, PSMA-targeted small molecule and demonstrate gamma-ray radioscintigraphic imaging of living humanprostate cancer cells.
Authors: P M Smith-Jones; S Vallabahajosula; S J Goldsmith; V Navarro; C J Hunter; D Bastidas; N H Bander Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: Martin G Pomper; John L Musachio; Jiazhong Zhang; Ursula Scheffel; Yun Zhou; John Hilton; Atul Maini; Robert F Dannals; Dean F Wong; Alan P Kozikowski Journal: Mol Imaging Date: 2002 Apr-Jun Impact factor: 4.488
Authors: Kelly Davis Orcutt; Khaled A Nasr; David G Whitehead; John V Frangioni; K Dane Wittrup Journal: Mol Imaging Biol Date: 2011-04 Impact factor: 3.488
Authors: Kai Bao; Jeong Heon Lee; Homan Kang; G Kate Park; Georges El Fakhri; Hak Soo Choi Journal: Chem Commun (Camb) Date: 2017-01-13 Impact factor: 6.222
Authors: Hak Soo Choi; Wenhao Liu; Preeti Misra; Eiichi Tanaka; John P Zimmer; Binil Itty Ipe; Moungi G Bawendi; John V Frangioni Journal: Nat Biotechnol Date: 2007-09-23 Impact factor: 54.908
Authors: Ralf Lesche; Georg Kettschau; Alexey V Gromov; Niels Böhnke; Sandra Borkowski; Ursula Mönning; Christa Hegele-Hartung; Olaf Döhr; Ludger M Dinkelborg; Keith Graham Journal: Eur J Nucl Med Mol Imaging Date: 2013-08-17 Impact factor: 9.236
Authors: Kamala Kesavan; Judson Ratliff; Eric W Johnson; William Dahlberg; John M Asara; Preeti Misra; John V Frangioni; Douglas B Jacoby Journal: J Biol Chem Date: 2009-12-15 Impact factor: 5.157
Authors: Kumar R Bhushan; Preeti Misra; Fangbing Liu; Sanjeev Mathur; Robert E Lenkinski; John V Frangioni Journal: J Am Chem Soc Date: 2008-12-31 Impact factor: 15.419
Authors: Fangbing Liu; Preeti Misra; Elaine P Lunsford; Joanne T Vannah; Yuxia Liu; Robert E Lenkinski; John V Frangioni Journal: Breast Cancer Res Treat Date: 2009-09-17 Impact factor: 4.872